The expression of BST2 in human and experimental mouse brain tumors

Experimental and Molecular Pathology

Volumn 91, Issue 1, 2011, Pages 440-446

  Wainwright, Derek A ^a   Balyasnikova, Irina V ^a   Han, Yu ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bone marrow stromal cell antigen; BST2; CD137; Gene therapy; Glioblastoma; Glioma; HM1.24; Immunotherapy; PDCA 1

Indexed keywords

BONE MARROW STROMAL CELL ANTIGEN 2; CELL ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; ASTROCYTOMA; BONE MARROW STROMAL CELL ANTIGEN 2 GENE; CANCER GRADING; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION;

ANIMALS; ANTIGENS, CD; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLIOMA; GPI-LINKED PROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL;

MUS;

EID: 79957455622     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.04.012     Document Type: Article

References (14)

1. Blasius A.L., et al. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J. Immunol. 2006, 177:3260-3265.
2. Cao W., et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 2009, 206:1603-1614.
3. Chiriva-Internati M., et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 2003, 102:3100-3107.
4. Goto T., et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994, 84:1922-1930.
5. Ishikawa J., et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995, 26:527-534.
6. Kawai S., et al. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci. 2008, 99:2461-2466.
7. Neil S.J., et al. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
8. Ohtomo T., et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 1999, 258:583-591.
9. Ozaki S., et al. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specifc antigen, HM1.24. Blood 1997, 90:3179-3186.
10. Stupp R., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
11. Szatmári T., et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 2006, 97:546-553.
12. Wainwright D.A., et al. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One 2010, 5:e15390.
13. Wang W., et al. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol. Immunother. 2009, 58:967-976.
14. Wong Y.F., et al. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 2007, 26:1971-1982.